Core B is the Nuclear Medicine Core and is responsible for the following: 1. Preparation of trace-labeled [131]l-BC8 Ab, [111]In labeled DOTA-BC8 Ab, [86]Y labeled DOTA-BC8 Ab, [111]In labeled DOTA-1F5 Ab, and [111]In labeled DOTA-biotin for evaluation of biodistributions in patients with AML, ALL, MDS, and NHL. (Projects 1, 2 and 3) 2. Performance of serial quantitative gamma camera imaging a. Performance of planar imaging in multiple projections in leukemia and lymphoma patients infused with trace-labeled [131]l-anti-CD45 (BCS), [111]In-DOTA BC8, or [111]In labeled DOTA-anti CD20 (1F5) antibodies; or with BC8-streptavidin (BC8-SA) conjugate followed by [111]In labeled DOTA-biotin (Projects 1, 2 and 3) b. Performance of SPECT imaging in one or more body regions for 3D reconstruction of uptake in normal organs and tumor to estimate or normalize uptake for dosimetry evaluation in patients with measurable lymphoma (one SPECT scan per patient performed 24 hours after infusion). (Projects 2 &3) c. Performance of sequential biodistribution and dosimetry studies comparing: i. [111]In labeled DOTA-anfi-CD45 (BCS) and [111]In labeled DOTA-anti CD20 (1F5) antibodies in patients with NHL (Project 2) ii. [111]In labeled DOTA-anti-CD45 (BCS) and [86]Y labeled DOTA BCS Ab in patients with NHL (Project 2) iii. [111]In labeled DOTA-anfi-CD45 (BCS) Ab vs BCS-SA followed by [111]In labeled DOTA biotin in patients with leukemia and lymphoma. (Project 3) 3, Performance of PET imaging on days 0, 1, 2 and 3 in patients with NHL lymphoma after trace-labeled infusion of [86]Y-DOTA anti-CD 45 (BCS) Ab (Project 2) 4, Quantification of biodistribution and estimate radiation absorbed doses of [131]l-BC8, [111]In DOTA-BC8 Ab, [111]In DOTA-1F5 Ab, and [111]In labeled DOTA biotin for evaluation and treatment of patients with [131]I - or [90]Y-labeled anti-CD 45 (BC8) Ab (Projects 1 and 2) or BC8-SA followed by [90]Y labeled DOTA biotin. (Project 3) 5. Preparation and administration of therapeutic doses of [131]I or [90]Y-DOTA-BC8 antibodies and [90]Y-labeled DOTA biotin for treatment of patients with lymphoma and leukemia, (Projects 1, 2 and 3) 6. Provision of radiation safety monitoring and counseling for patients and staff. (Projects 1, 2, and 3)

Public Health Relevance

Nuclear medicine physicians on Core B attach radioactive isotopes to monoclonal antibodies and inject them into patients with leukemia, lymphoma, and myelodysplasia. Nuclear medicine imaging techniques are then used to determine if the radiolabeled antibodies target properly to tumor sites, based on dosimetry done by Dr. Darrell Fisher. If the antibodies target, the nuclear medicine physicians administer therapeutic doses of the radiolabeled antibodies to treat the cancers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA044991-26
Application #
8719027
Study Section
Special Emphasis Panel (ZCA1-RPRB-J)
Project Start
Project End
Budget Start
2014-08-01
Budget End
2015-07-31
Support Year
26
Fiscal Year
2014
Total Cost
$601,896
Indirect Cost
$120,750
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Phipps, Colin; Gopal, Ajay K; Storer, Barry E et al. (2015) Autologous transplant for relapsed follicular lymphoma: impact of pre-transplant rituximab sensitivity. Leuk Lymphoma 56:92-6
Palanca-Wessels, Maria Corinna; Press, Oliver W (2014) Advances in the treatment of hematologic malignancies using immunoconjugates. Blood 123:2293-301
Balkin, Ethan R; Kenoyer, Aimee; Orozco, Johnnie J et al. (2014) In vivo localization of ??Y and ยน??Lu radioimmunoconjugates using Cerenkov luminescence imaging in a disseminated murine leukemia model. Cancer Res 74:5846-54
Lionberger, Jack M; Pagel, John M; Sandhu, Vicky K et al. (2014) Outpatient bendamustine and idarubicin for upfront therapy of elderly acute myeloid leukaemia/myelodysplastic syndrome: a phase I/II study using an innovative statistical design. Br J Haematol 166:375-81
Mawad, Raya; Gooley, Ted A; Rajendran, Joseph G et al. (2014) Radiolabeled anti-CD45 antibody with reduced-intensity conditioning and allogeneic transplantation for younger patients with advanced acute myeloid leukemia or myelodysplastic syndrome. Biol Blood Marrow Transplant 20:1363-8
Gopal, Ajay K; Gooley, Ted A; Rajendran, Joseph G et al. (2014) Myeloablative I-131-tositumomab with escalating doses of fludarabine and autologous hematopoietic transplantation for adults age ? 60 years with B cell lymphoma. Biol Blood Marrow Transplant 20:770-5
Matesan, Manuela; Rajendran, Joseph; Press, Oliver W et al. (2014) 90Y-ibritumomab tiuxetan therapy in allogeneic transplantation in B-cell lymphoma with extensive marrow involvement and chronic lymphocytic leukemia: utility of pretransplantation biodistribution. Nucl Med Commun 35:1132-42
Cassaday, Ryan D; Guthrie, Katherine A; Budde, Elizabeth L et al. (2013) Specific features identify patients with relapsed or refractory mantle cell lymphoma benefitting from autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 19:1403-6
Cairo, Mitchell S; Woessmann, Willi; Pagel, John (2013) Advances in hematopoietic stem cell transplantation in childhood and adolescent lymphomas. Biol Blood Marrow Transplant 19:S38-43
Mawad, Raya; Lionberger, Jack M; Pagel, John M (2013) Strategies to reduce relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia. Curr Hematol Malig Rep 8:132-40

Showing the most recent 10 out of 94 publications